ABSTRACT. Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disorder in Caucasian populations, with an incidence of about 1 in 2000 live births, implying a carrier frequency of about 1 in 22 . In 1989, the C F gene was isolated and characterized and the major mutation (AF508), a 3-bp deletion that results in the loss of a phenylalanine residue a t position 508, was detected. To determine the frequency of the AF508 mutation and the predicted number of additional mutations in our population, we have undertaken a collaborative study of 215 C F patients and 175 C F parents in Switzerland. The AF508 mutation in exon 10 has been found in 70% of the C F chromosomes, and the exon-11 mutation R553S seems to be the second most common C F mutation in our population, with a frequency of 5.3' 70, whereas the G551D mutation (also in exon 11) has not been detected a t all. Haplotype determination of 430 C F and 175 normal chromosomes using XV-2c, KM19, MP6d-9, and 53.11 has been proven to be very helpful in providing additional carrier risk calculations: Haplotypes 1 (1221), 2 (1222), 6 (2111), and 7 (2221) increase the risk of being a carrier from 1 in 5 5 (haplotype 6) to 1 in 1 7 (haplotype I), whereas haplotypes 3 (1122), 4 (1112), 8 (2222) and 10 (1111) lower the risk from 1 in 144 (haplotype 3) to 1 in 1678 (haplotype 10). WIoreover, the mutation R553X shows strong correlation with haplotype 3, leading to the suggestion that haplotypes 1, 2, 5, and 6 may account for four additional mutations in Switzerland. It is concluded that haplotype analyses should be offered to partners of individuals with a family history of CF, giving a more informative carrier risk estimation than the global 1 in 80. For couples a t increased risks, where no completely reliable prenatal tests exist, microvillar enzyme testing in combination with DNA analysis is recommended. (Pediatu Res  30: 304-308, 1991) Abbreviations CF, cystic fibrosis RFLP, restriction fragment length polymorphism PCR, polymerase chain reaction CF is the most common severe autosomal recessive genetic disorder in Caucasian populations. with an incidence of about 1 in 2000 live births, implying a carrier frequency of about 1 in 22. Its severity of expression in patients varies widely, and the disease involves multiple organ systems. Many of the symptoms of cystic fibrosis are associated with defective transport of chloride ions across epithelia, suggesting that the CF gene product, called the CF transmembrane conductance regulator, might be involved in the regulation or structure of the chloride channel (1). A review of the physiologic and molecular aspects of CF has recently been p~~blished (2) .
One of the major breakthroughs in CF research was the mapping of the gene to chromosome 7q21-7q3 1 by genetic linkage analysis (3) (4) (5) . Subsequently, DNA sequences progressively closer to the gene were identified (6) (7) (8) . DNA polymorphism~ presenting allelic association with the CF gene (linkage disequilibrium) were found, implying that the majority of the CF cl~romosomes arose from one or a few mutational events (9) (10) (11) . RFLP analysis of families that showed recombination between the markers and the disease, plus long-range restriction mapping, located the gene to a region spanning approximately 500 kb (12) (13) (14) (15) . In 1989, the gene was finally cloned. It is predicted to encode a protein of 1480 amino acids; the major mutation AF508, a 3-bp deletion that results in the loss of a phenylalanine residue at position 508. has been defined (16-1 8). The frequency of AF508 has found to be 68-78% in North American (18), British, and Dutch patients (19) , whereas in Spanish and Italian populations and in black American patients the deletion is present in only 5 1-58% (19) and 37% (1 1) of the CF chromosomes. respectively. So, it seems likely there will be a large number of CF mutations including deletions (1 7), fraineshift mutations (20) , and point mutations (21, 22) . More than 100 mutations have been detected so far, most of which are rarely found. However, two rather common CF mutations localized in exon 11 have recently been described by Cutting et 01. (22) : The G55 ID mutation, causing an amino-acid substitution (G1784+A: Gly55 1+Asp), and the nonsense mutation R553X, creating a premature termination signal (C1789-T; k g 5 5 3 4 Stop). The ability to detect CF n~utations at the DNA level offers the opportunity of more precise carrier detection and prenatal diagnosis. But effective DNA-based testing requires the definition of all CF mutations and their frequencies for individual populations because of frequency variations anlong different geographic locations.
We previously reported on DNA marker haplotypes of RFLP flanking the CF gene in CF families of Switzerland (23) . The aim of this study was, one. to improve in our country carrier testing. prenatal diagnosis, and risk calculations by combining direct mutation analyses and haplotype information. Two. we wanted t o contribute firr-ther information on mutation and haplotype frequencies to the C F mutation research in Europe.
T o determine the AF508-deletion frequency and the number of additional mutations in our population, we have undertaken a collaborative study of the C F patients in Switzerland. Here, we report the results of AF508-, R553X-, and G55 ID-screening by PCR analysls and the haplotype distribution of C F and normal chromosomes that has been generated by RFLP analyses using the markers XV-2c, KM 19, MP6d-9, and pJ3.1 I.
strand DNA was purified from primers and enzyme by alcohol precipitation and one fifth of the total used for sequencing with the T 7 DNA sequencing kit (Pharmacia, Diibendorf, Switzerland). Twenty pmol of the primer 1 li-5 was used as the sequencing primer.
Sequence details have generously been provided by members of the international C F genetic analysis consortium.
Risk calc~~lutions. Carrier risks for non-AF508 chromosomes of particular haplotypes were calculated by combined statistical analysis including the Hardy-Weinberg equilibrium and the MATERIALS AND METHODS ~a~e s ' theorem according to Lemna pt ai. (30) and Watson el a/.
(3 I) using the formula R(x) = (pc/C):[pc/C + (1 -p)n/N], where S14;rcxts. We studied 430 C F chromosomes, from 21 5 patients P = prior risk that a chromosolne carries the C F gene (1/40), in whom the diagnosis of C F met standard criteria (24) , obtained C = number of non-AF508, non-R553X C F chromosomes carfrom the five university genetic centers in Switzerland. In addi-v i n g haplotype x, C = total number of C F chromosomes (4301, tion. 175 normal chromosomes from 175 parents heterozygous n = number of normal ~h~~m o s o m e s with haplotype x, and N for C F have been analvzed for h a~l o t v~e determination. All = number of normal chromosomes (175).
. ,& patients and parents are native Swiss from central, western, northern, and eastern Switzerland, mostly of Celtic and Germanic origin.
DNA analyses. DNA extraction from whole blood containing EDTA as an anticoagulant, restriction enzyme digestion, Southern blotting, and hybridization using oligo-labeled probes were performed as described before (23) .
RFLP were determined for the XV-2c/TaqI, (8), KM19/PstI (25). MP6d-9lMspI (26), and 53.1 I/MspI (4) probes and haplotypes were constructed using the C F patients' genotypings to establish phase.
The AF508 deletion was detected by amplification of genomic DNA by PCR (27) followed by vertical electrophoresis in a polyacrylamide gel and ethidium bromide staining (28) . The PCR primer sequences were 5'-GTTTTCCTGGATTATGCCT-GGCAC-3' and 5'-GTTGGCATGCTTTGATGACGCTTC-3' ( 17) .
The amplification product of the normal allele is 98 bp and of the deleted allele is 95 bp. Two hundred pmol of each primer were used with 200-300 ng of genomic DNA and 5.0 U TaqIpolymerase (Perkin-Elmer Cetus, Kuesnacht, Switzerland) in a total volume of 100 ILL under paraffin oil. Annealing conditions were 64°C for 90 s, extension at 72°C for 120 s, and denaturation a t 94°C for 60 s, for 28 cycles with a final cycle of 5 min for extension in a Perkin-Elmer Amplification System. About one fifth of the amplification product was applied on a 20-cm 12% polyacrylamide gel and run at 90 V in Tris-borate/EDTA buffer over night. Fragments were visualized and photographed after staining with ethidium bromide and illuminating them with 306 nm UV light.
The R553X mutation was detected by PCR amplification using exon-1 1 primers 1 1 i-5'-CAACTGTGGTTAAAGCAA-TAGTGT and I 1 i-3'-GCACAGATTCTGAGTAACCATAAT (32) . resulting in a 425-bp fragment. HincII digestion of genomic DNA amplified from normal exon-1 1 sequence produces fragments of 186 and 239 bp. The R553X as well as the G55 I D mutation cause the loss of the normal HincII recognition site. Normal exon-1 1 amplification products cannot be cut with MhoI, whereas the G551D mutation creates a new hfhol-site, resulting in two fragments of 182 and 243 bp.
DNA of non-AF508-CF chromosomes was amplified with exon-1 l primers and subsequently cut with HincII. Amplification products that showed no HincII restriction site were additionally cut with hfboI. PCR and gels were performed as described for AF508 analyses.
The mutations were confirmed by dideoxy sequencing (29) on single strand templates generated by asymmetric reamplification, using an internal primer located 3' to exon I I (Malik NJ, Hofmann S, Reiser P, Biihler EM, unpublished experiment). Asymmetric amplification was carried out using 2 ILL of the initial amplification products, an amplification mixture containing 1 pmol of primer 1 li-5, and 50 pmol of primer 1 lint-3 (5'-GTGATTCTTAACCCACTAGCC-3'). The resultant single RESULTS AF508-deletion. We analyzed 430 C F cl~romosomes for the presence of AF508 and found the frequency of the deletion to be 70% (301 out of 430). One hundred nine (5 1%) of the 215 patients were found to be homozygous for the AF508 mutation, 83 (38%) were compound heterozygous, and 23 (I 1%) did not bear the deletion on either chromosome, being either compound heterozygotes for two unknown mutations or homozygotes for one not yet defined mutation.
R553X und G551D n~lltntions. The remaining 30% of C F chromosomes (129 out of 430) without the AF508 mutation have been amplified with the primer pair of exon 1 1 followed by HincII digestion. DNA that was not cut. demonstrating loss of the restriction site, was additionally digested by MboI to test it for G551D. After confirmation by sequencing, all of our exon 11 mutations turned out to be R553X mutations. The R553X mutation has been detected in 23 (5.35%) of the 430 CFchromosomes and in 23 (18%) of the 129 non-AF508 chromosomes. Three patients showed homozygosity for R553X, whereas 17 were compound heterozygotes. In 14 of these 17 patients, the R553X mutation was paired with the AF508 deletion.
Hap/otjlpes. The marker allele constellations for XV-2c/ K M 19/MP6d-91J3.11 have been determined in 430 C F chromosomes and in 175 normal chromosomes and were expected to occur in 16 different haplotypes. The presence or absence of the AF508 deletion was correlated with haplotypes, and the haplotype distributions for non-AF508 C F chromosomes as well as for normal chromosomes are presented in Figures 1 and 2 (only 1 1 out of 16 haplotypes have been found). Figure 1 shows the haplotype distributions of 310 AF508-bearing C F chromoson~es and 129 non-AF508 C F chromosomes: 70.4% (212 out of 301) of the AF508-bearing chromosomes are associated with haplotype 1 (122 1); 27.3% (82 out of 301) are associated with haplotype 2 (1222); and foul-and three chromosomes, respectively, show haplotypes 1 1 (1 121) (1.3%) and 8 (2222) (1 %). The data confirm that the AF508 deletion is strongly associated with the marker allele constellation 122 1, which has previously been reported to be the most common haplotype among C F chromosomes in Caucasians (9-1 1, 20) . However, the fact that the AF508 deletion was not found on all C F chromosomes carrying haplotype 1 and the observation of unequal distribution of the other haplotypes suggested additional moderately common mutations correlated with particular haplotypes in our patients. The haplotype distribution of the non-AF508 C F chromosomes is more heterogeneous: The most common haplotype is number 3 (1 122), detected in 25 (19.4%) of the 129 C F chromosomes without the AF508 mutation and strongly linked to the exon-l l mutation R553X. Every R553X-bearing chromosome had the haplotype 3, and, conversely, all but two haplotype 3 chromosomes showed the R553X mutation. (22 out of 129) and 6 (22 out of 129) are also rather frequent, occurring in 13-1 7% of non-AF508 chromosomes; they may be specifically correlated with four additional mutations. Haplotypes 4 and 7 are present in eight of 128 non-AF508 C F chromosomes each, whereas haplotypes 8 (three out of 129), 9 (two out of 129), and 10 (one out of 129) are rarely found. Figure 2 demonstrates the haplotype distributions of normal chrotnosonies verslrs C F chromosomes without the AF508 deletion and without the R553X mutation. Normal chromosomes seem to be preferably associated with haplotypes 5 (38 out of 175; 22%). 10 (35 out o; 175; 20%), 4 (31 out of 175; 18%). and 6 (25 out of 175; 14%), whereas haplotypes 2 (15 out of 175; 9%), 8 (10 out of 175; 6%). 1 (seven out of 175; 4%), and 3 (six out of 175; 3%) are represented in lower frequencies and haplotypes 7 and 1 I are rarely f o~~n d (four out of 175; 2%). Moreover, haplotypes 12-16 (121 1/1212/2121/2212/2211) have not been detected at all, either in C F or in normal chromoson~es. When comparing the haplotype frequencies of normal and non-AF508, non-R553X chromosomes, haplotypes 10, 4, 3, and 8 indicate a normal chromosome with a very high probability. In contrast, the risk of can-ying a C F mutation is obviously increased in the presence of haplotypes 1, 2, 6, and 7. Table 1 shows the risks for non-AF508, non-R553X chromosomes of specific haplotypes to be C F chromosomes and the carrier risk calculations for individuals of specific non-AF508, non-R553X genotypes.
DISCUSSION
Previous results provided by the original North American study (1 8) and data reported by other groups (19) indicated that the AF508 deletion is present in more than two thirds of C F chromosomes in Northern Europe. We have analyzed 2 15 patients from Switzerland and found the AF508 frequency to be 70%. This finding supports the hypothesis that the predominant C F mutation. present throughout Europe, originated in a specific location before spreading according to a northwest-southeast gradient to all populations by migration (1 9, 32).
Examination of exon I I revealed only one of the four mutations described by Cutting er ul. (22) . R553X. This nonsense mutation was found on 23 of 129 non-AF508 C F chromosomes, resulting in a frequency of 18%. It therefore seems to be the second most common C F mutation in our population. Cutting et ul. (22) reported the G55 1 D mutation (which we did not detect at all) to be found in 4% of C F chromosornes of Caucasian and the R553X mutation to be found in 5% of C F chromosomes of black Americans. Provisional data from different European countries show 0.5-13% of the non-AF508 C F chromosomes carrying the G55 I D mutation and 1-10% of the non-AF508 C F Identification of the AF508 and R553X mutations allow the detection of 75% of C F chromosomes in Switzerland, raising the question of population-based screening for carriers. The detection of multiple individually rare mutations (more than 100 at the time ofwriting) makes carrier testing more and more difficult, and. if no more than 95% of carriers can be detected, screening may not be advisable (33, 34) . However, carrier testing that is nearly 100% informative can be offered to all individuals with a fhmily history of CF, inasmuch as carrier detection can be performed by linkage analyses in addition to mutation analyses.
The association between DNA polymorphism haplotypes and specific gene mutations has been proven to be of great value in a variety of autosomal recessive disorders. Therefore, we determined the haplotypes of 301 AF508 and 129 non-AF508 C F chroniosomes and 175 normal chromosomes using three DNA markers (XV-2c, KM19, MP6d-9) centromerlc and one marker (53.1 I) telomeric to the C F gene. The AF508 deletion was almost exclusively associated with haplotypes 1 (70.5%) and 2 (27%), which have previously been found to occur most commonly in C F chron~osomes (10, 1 I , 23). Haplotype frequencies of the non-AF508 C F chromosomes may differ from country to country depending on ethnic background, for example racial admixture. and on the location and the moment when a new mutation occurred. The strong correlation of the R533X mutation with haplotype 3 suggests that haplotypes 1, 2, 5, and 6 may be associated with at least four other specific mutations. As long as these mutations are not known, haplotype frequencres can be used for carrier risk calculations.
Screening for AF508 and R553X detects the mutation in 75% of C F chromosomes in Switzerland. If a non-related partner of a n individual heterozygous for C F tests negative for AF508 and R553X. his risk of being a carrier decreases from the population risk of I in 30 down to I in 80. Combination with haplotype data provides still more accurate calculations: Table 1 shows the risk that a non-AF508, non-R553X chromosome of a particular haplotype is a C F chromosome and the carrier risks for individuals of specific non-AF508, non-R553X genotypes. The data demonstrate that haplotypes generated from the marker allele constellation of XV-2c, KM 19, MP6d-9, and 53.1 1 influence strongly carrier risk calculations. Haplotypes 1 , 2. 6, and 7 increase the risk of being a carrier from 1 in 55 (haplotype 6) to I in 17 (haplotype l)? whereas haplotypes 3, 4, 8, and 10 lower the risk from 1 in 144 (haplotype 3) to 1 in 1678 (haplotype 10). However, the global risk of 1 in 80 is not markedly changed by haplotype 5, inasmuch as it shows approximately the same frequency in normal and non-AF508 chromosonles. Mutations on chromosomes carrying haplotype 5 may be of more recent origin. Thus, haplotype analyses that give a more informative risk estimation than the global 1 in 80 should be offered to partners of individuals with a family history of CF. Where one partner is a known carrier and the other has genotype 414. the risk in any pregnancy decreases from I in 320 to 1 in 744, whereas for genotype 111 the risk increases to 1 in 68. For couples at increased risk, there are n o completely reliable prenatal tests; however, microvillar enzyme testing in combination with DNA analysis is recommended in this situation and will provide the most help possible to the couple i11 deciding whether they want the pregnancy to be interrupted or continued.
On the basis of PCR analyses for AF508 and R553X in conjunction with DNA marker haplotype comparisons, we conclude that there are at least four additional C F mutations in our population. Three of our C F patients have been found to be homozygous for R553X; they present with normal weight and low Crispin Norman scores up to the age of 10 and rapid progression fro111 the age of 12, suggesting a two-stage course. Further studies on clinical symptoms in correlation with haplotypes are under investigation, and we hope to determine precisely what the additional C F mutations are in our population. 
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